The Vaccine Alliance, Gavi, has outlined a roadmap to ensure stable supply of HPV vaccine for adolescent girls in lower-income countries, saying with over 348,000 deaths in 2022, cervical cancer continues to kill women globally.
The plan, detailed in a new report, comes after proactive efforts by Gavi and manufacturers increased vaccine availability. According to Gavi’s projections, overall supply is expected to meet demand by 2025, but careful management is crucial throughout 2024.
The roadmap, developed in collaboration with key partners, emphasises collaboration between governments, manufacturers, and Gavi itself to establish a dependable supply chain for the next decade.
Chief Programme Officer at Gavi, Aurélia Nguyen, said: “For far too long, lower-income countries have lacked access to HPV vaccines.
“To reach our goal of protecting 86 million girls by 2025, we need meticulous management of existing doses and continued donor and manufacturer support.”
Nguyen highlighted the importance of a growing supplier base and the World Health Organisation (WHO)’s recommendation for a single-dose regimen as reasons for Gavi’s urgent focus on scaing up access and securing long-term supply.
